Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2019

View Archived Issues

Opioids impervious to GLP-1 agonists

Unexpected role of reduced myelination in Williams syndrome

Missense mutation in myoglobin causes an adult-onset autosomal dominant myopathy

STELLAR-3 study of selonsertib does not meet prespecified week 48 primary endpoint

Janssen initiates phase I study of JNJ-67571244 in patients with AML or MDS

Allegro Ophthalmics names new anti-integrin product for dry eye disease

EDP-514 demonstrates potent preclinical antiviral activity

CYFRA 21-1 as novel prognostic marker in advanced liver disease

ANGPTL2 knockdown results in mouse model of spontaneous aortic valve stenosis

Tachykinin NK1 receptor antagonists suppress leukemic cell growth

Kezar Life Sciences presents new compounds with antitumoral activity

DOC2A Ca2+ sensor is overexpressed in temporal lobe epilepsy in humans and rat models

OMPTA agent POL-7306 is potent against Gram-negative bacteria in vitro and in vivo

GlaxoSmithKline patents new HBV inhibitors

Takeda presents JAK inhibitors

hSTING modulators disclosed in GlaxoSmithKline patent

Takeda identifies glutamate receptor agonists

Structure, activity described for AMG-510, the first-in-human covalent inhibitor of KRAS G12C

University of Miami presents new compositions for epidermolysis bullosa

FDA approves Duobrii for plaque psoriasis

Pimavanserin begins phase III for major depressive disorder

ReNeuron reports new data from phase I/IIa study of hRPC therapy candidate for retinitis pigmentosa

Japanese phase III study of delgocitinib in pediatric atopic dermatitis meets primary endpoint

Novartis describes activity in vivo of TLR7 agonist LHC-165, now entering phase I

NIH to send 3-D tissue chips into space to study aging and diseases accelerated in microgravity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...